Summary

The bioconjugation market is expected to grow to USD 10.86 billion by 2029, up from USD 5.27 billion in 2024, at a CAGR of 15.6% between 2024 and 2029. Several key factors impact the growth of the bioconjugation market. The development of targeted therapeutics such as ADCs is expected to be greatly supported by bioconjugation, as the need for more accurate and potent cancer treatments grows. Furthermore, there is a growing focus on technological developments and outsourcing services. Furthermore, emerging countries provide significant development opportunities, and the expanding applications of bioconjugation are expected to drive the market further.
“The antibody conjugation segment accounted for the largest share of by conjugation type segment for the bioconjugation services market in 2023.”
In 2023, the antibody conjugation segment accounted for the largest share of the global bioconjugation services market by conjugation type. The antibody conjugation segment dominates the bioconjugation services market because it is widely used in developing targeted treatments, particularly for cancer. Antibody-drug conjugates (ADCs) enable accurate drug delivery by targeting specific antigens on tumor cells, minimizing off-target effects and toxicity. The favourable results of ADCs in clinical trials, as well as their approval to treat a variety of malignancies, including HER2-positive breast cancer, have increased demand for antibody-based conjugation services.
“The antibodies segment accounted for the largest share of by biomolecule type segment for the bioconjugation products market in 2023.”
In 2023, the antibodies segment accounted for the largest share of the global bioconjugation products market by biomolecule type. The most prominent biomolecule type in the bioconjugation products market is antibodies, especially monoclonal antibodies, which are dominantly used in the development of Antibody-Drug Conjugates (ADCs) with higher accuracy in targeting. Antibodies are integrally used in oncology and have led to several FDA-approved ADC therapies such as Adcetris and Kadcyla. These therapeutic antibodies conjugated with cytotoxic drugs through bioconjugation techniques allow for targeted treatment while minimizing systemic toxicity. Increasing clinical trials and FDA approvals for the drugs based on antibodies further drive the growth of this segment.
“In 2023, the US remained to dominate the bioconjugation market.”
The US dominated the North American bioconjugation market in 2023. The US is the world's largest biopharmaceutical market and the leader in biopharmaceutical research and investment. The United States also has a strong healthcare infrastructure, which encourages research and development in the life sciences. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, the growing prevalence of cancer is also driving the growth of the bioconjugation market.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other
executives from various key organizations operating in the bioconjugation
marketplace.
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%


Danaher Corporation (US); Lonza (Switzerland); Thermo Fisher Scientific Inc. (US); Merck KGaA (Germany); AbbVie Inc. (US); WuXi Biologics (Cayman) Inc. (China); Sartorius AG (Germany); are some of the key players in the bioconjugation market.

The study includes an in-depth competitive analysis of these key players in the bioconjugation market, with their company profiles, recent developments, and key market strategies

Research Coverage:
This research report categorizes the bioconjugation market by product type (consumables { reagents and kits [linker and crosslinking reagents & kits, labeling reagents & kits, modification reagents & kits, other reagents & kits], labels [fluorescent tags, enzymes, haptens, polymers, bead coupling, other labels], other consumables}, instruments {chromatography systems, mass spectrometers, spectroscopy instruments, flow cytometers, electrophoresis equipment, filtration systems, mixers/shakers, incubators, other instruments}]), technique (chemical conjugation, click chemistry, enzyme-mediated conjugation, photoreactive crosslinking, other techniques), biomolecule type (antibodies, peptides, proteins, oligonucleotides, other biomolecules), application (therapeutics {antibody-drug conjugates (ADCs), peptide-drug conjugates, protein-drug conjugates, other therapeutic applications}, research & development, diagnostics), end user (pharmaceutical & biotechnology companies, CROs & CMOs, academic & research institutes, hospitals and clinical/diagnostic laboratories), service type ( custom synthesis & conjugation services, analytical & characterization services, scale-up & manufacturing services, other services), technique (chemical conjugation, click chemistry, enzyme-mediated conjugation, photoreactive crosslinking, other techniques), conjugation type (antibody conjugation, peptide conjugation, protein conjugation, oligonucleotide conjugation, other conjugation services), application (therapeutics, research & development, diagnostics), end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals and clinical/diagnostic laboratories), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the bioconjugation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the bioconjugation market.
Reasons to buy this report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall bioconjugation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (growing demand for targeted therapies, increasing investments in biopharmaceutical R&D, rising demand for outsourcing services, expanding pipeline of bioconjugated drugs, advancements in bioconjugation technologies), restraints (high cost of bioconjugate development & manufacturing, stringent regulatory requirements), opportunities (high growth potential of emerging economies, expanding applications of bioconjugation), and Challenges (technical complexities) influencing the growth of the market.
• Product/Service Development/Innovation: Detailed insights on newly launched products/services of the bioconjugation market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioconjugation market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product/service offerings of leading players like Danaher Corporation (US), Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), AbbVie Inc. (US), WuXi Biologics (Cayman) Inc. (China), Sartorius AG (Germany), Bio-Rad Laboratories, Inc. (US), among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 58
1.1 STUDY OBJECTIVES 58
1.2 MARKET DEFINITION 58
1.3 MARKET SCOPE 58
1.3.1 MARKETS COVERED 59
1.3.2 INCLUSIONS & EXCLUSIONS 60
1.3.3 YEARS CONSIDERED 61
1.3.4 CURRENCY CONSIDERED 61
1.4 MARKET STAKEHOLDERS 61
2 RESEARCH METHODOLOGY 62
2.1 RESEARCH DATA 62
2.1.1 SECONDARY DATA 63
2.1.2 PRIMARY DATA 63
2.2 MARKET ESTIMATION METHODOLOGY 65
2.2.1 MARKET ESTIMATION 65
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 68
2.2.3 TOP-DOWN APPROACH 68
2.3 MARKET GROWTH RATE PROJECTION 70
2.4 DATA TRIANGULATION 72
2.5 RESEARCH ASSUMPTIONS 73
2.6 RESEARCH LIMITATIONS 74
2.7 RISK ANALYSIS 74
3 EXECUTIVE SUMMARY 75
4 PREMIUM INSIGHTS 83
4.1 BIOCONJUGATION MARKET OVERVIEW 83
4.2 NORTH AMERICA: BIOCONJUGATION PRODUCTS MARKET, BY APPLICATION AND COUNTRY (2023) 84
4.3 BIOCONJUGATION PRODUCTS MARKET, BY TYPE (2023) 84
4.4 BIOCONJUGATION PRODUCTS MARKET, BY END USER (2023) 85
4.5 BIOCONJUGATION SERVICES MARKET, BY TYPE (2023) 85
4.6 BIOCONJUGATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 86
 
5 MARKET OVERVIEW 87
5.1 INTRODUCTION 87
5.2 MARKET DYNAMICS 88
5.2.1 DRIVERS 89
5.2.1.1 Growing demand for targeted therapies 89
5.2.1.2 Increasing investments in biopharmaceutical R&D 90
5.2.1.3 Rising demand for outsourcing services 91
5.2.1.4 Expanding pipeline of bioconjugate drugs 92
5.2.1.5 Advancements in bioconjugation technologies 93
5.2.2 RESTRAINTS 94
5.2.2.1 High cost of bioconjugate development & manufacturing 94
5.2.2.2 Stringent regulatory requirements 95
5.2.3 OPPORTUNITIES 95
5.2.3.1 High growth potential of emerging economies 95
5.2.3.2 Expanding applications of bioconjugation 96
5.2.4 CHALLENGES 96
5.2.4.1 Technical complexities 96
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97
5.4 PRICING ANALYSIS 98
5.4.1 INDICATIVE PRODUCT PRICING ANALYSIS, BY KEY PLAYER 98
5.4.2 INDICATIVE PRODUCT PRICING ANALYSIS, BY REGION 99
5.5 SUPPLY CHAIN ANALYSIS 100
5.6 VALUE CHAIN ANALYSIS 102
5.7 ECOSYSTEM ANALYSIS 104
5.7.1 BIOCONJUGATION MARKET: RAW MATERIAL SUPPLIERS 104
5.7.2 BIOCONJUGATION MARKET: PRODUCT MANUFACTURERS 105
5.7.3 BIOCONJUGATION MARKET: SERVICE PROVIDERS 105
5.7.4 BIOCONJUGATION MARKET: END USERS 106
5.7.5 BIOCONJUGATION MARKET: REGULATORY BODIES 106
5.8 TECHNOLOGY ANALYSIS 107
5.8.1 KEY TECHNOLOGIES 107
5.8.1.1 Chemical conjugation 107
5.8.1.2 Enzymatic conjugation 107
5.8.1.3 Photochemical conjugation 108
5.8.1.4 Click chemistry 108
5.8.2 COMPLEMENTARY TECHNOLOGIES 108
5.8.3 ADJACENT TECHNOLOGIES 110
5.9 PATENT ANALYSIS 111
5.10 KEY CONFERENCES & EVENTS 113
 
5.11 REGULATORY LANDSCAPE 114
5.11.1 REGULATORY SCENARIO 114
5.11.1.1 North America 114
5.11.1.1.1 US 114
5.11.1.1.2 Canada 115
5.11.1.2 Europe 115
5.11.1.2.1 Germany 115
5.11.1.2.2 UK 115
5.11.1.3 Asia Pacific 115
5.11.1.3.1 Japan 115
5.11.1.3.2 China 115
5.11.1.4 Latin America 115
5.11.1.4.1 Brazil 115
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
5.12 INVESTMENT & FUNDING SCENARIO 119
5.13 PORTER’S FIVE FORCES ANALYSIS 120
5.13.1 THREAT OF NEW ENTRANTS 121
5.13.2 THREAT OF SUBSTITUTES 121
5.13.3 BARGAINING POWER OF BUYERS 121
5.13.4 BARGAINING POWER OF SUPPLIERS 121
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 121
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 122
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 122
5.14.2 BUYING CRITERIA FOR END USERS 123
5.15 TRADE ANALYSIS 125
5.16 IMPACT OF AI/GENERATIVE AI ON BIOCONJUGATION MARKET 128
6 BIOCONJUGATION PRODUCTS MARKET, BY TYPE 130
6.1 INTRODUCTION 131
6.2 CONSUMABLES 131
6.2.1 REAGENTS & KITS 135
6.2.1.1 Linker and crosslinking reagents & kits 138
6.2.1.1.1 Precision in conjugation reactions to boost demand 138
6.2.1.2 Labeling reagents & kits 141
6.2.1.2.1 Growing demand for enhanced diagnostic sensitivity to fuel uptake 141
6.2.1.3 Modification reagents & kits 144
6.2.1.3.1 Uptake of protein engineering for optimal behavior to support market growth 144
6.2.1.4 Other reagents & kits 147
 
6.2.2 LABELS 150
6.2.2.1 Fluorescent tags 153
6.2.2.1.1 Rising demand in imaging & diagnostics to drive market 153
6.2.2.2 Enzymes 156
6.2.2.2.1 Increasing utilization of western blotting & ELISA kits to fuel market 156
6.2.2.3 Haptens 159
6.2.2.3.1 Wide applications in immunoassays and vaccine development to support market growth 159
6.2.2.4 Polymers 162
6.2.2.4.1 Advancements in polymer-based drug delivery systems to drive market 162
6.2.2.5 Bead coupling 165
6.2.2.5.1 Utilization in magnetic bead-based immunoassays and cell separation to support market growth 165
6.2.2.6 Other labels 168
6.2.3 OTHER CONSUMABLES 171
6.3 INSTRUMENTS 174
6.3.1 CHROMATOGRAPHY SYSTEMS 177
6.3.1.1 Ability to offer precision and purification to drive market 177
6.3.2 MASS SPECTROMETERS 180
6.3.2.1 High uptake in bioconjugate characterization to drive market 180
6.3.3 SPECTROSCOPY INSTRUMENTS 183
6.3.3.1 Monitoring of bioconjugation reactions in real-time to fuel uptake 183
6.3.4 FLOW CYTOMETERS 186
6.3.4.1 Determination of therapeutic potential in ADCs to propel market 186
6.3.5 ELECTROPHORESIS EQUIPMENT 189
6.3.5.1 Increasing requirement for reliable analysis to support market growth 189
6.3.6 FILTRATION SYSTEMS 192
6.3.6.1 High purity requirements to support market growth 192
6.3.7 MIXERS & SHAKERS 195
6.3.7.1 Ability to ensure uniform conjugation reactions to boost demand 195
6.3.8 INCUBATORS 197
6.3.8.1 Integration of smart technologies for controlled environments to drive market 197
6.3.9 OTHER INSTRUMENTS 200
7 BIOCONJUGATION PRODUCTS MARKET, BY TECHNIQUE 203
7.1 INTRODUCTION 204
7.2 CHEMICAL CONJUGATION 204
7.2.1 HIGH DEMAND FOR ONCOLOGY ADCS AND VERSATILE TECHNIQUE TO PROPEL MARKET 204
 
7.3 CLICK CHEMISTRY 208
7.3.1 GROWING NEED FOR REGULATORY COMPLIANCE AND QUALITY ASSURANCE TO PROPEL MARKET 208
7.4 ENZYME-MEDIATED CONJUGATION 211
7.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND 211
7.5 PHOTOREACTIVE CROSSLINKING 214
7.5.1 DEVELOPMENT OF LIGHT-ACTIVATED THERAPEUTICS AND IMAGING AGENTS TO SUPPORT MARKET GROWTH 214
7.6 OTHER TECHNIQUES 217
8 BIOCONJUGATION PRODUCTS MARKET, BY BIOMOLECULE TYPE 221
8.1 INTRODUCTION 222
8.2 ANTIBODIES 222
8.2.1 EXPANDING THERAPEUTIC APPLICATIONS TO SUPPORT MARKET GROWTH 222
8.3 PEPTIDES 225
8.3.1 HIGH FLEXIBILITY AND DRUG DELIVERY EFFICIENCY TO FUEL UPTAKE 225
8.4 PROTEINS 228
8.4.1 INCREASING DEVELOPMENT OF ELISA AND PDCS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET 228
8.5 OLIGONUCLEOTIDES 231
8.5.1 GROWING UPTAKE IN GENE THERAPY TO SUPPORT MARKET 231
8.6 OTHER BIOMOLECULES 234
9 BIOCONJUGATION PRODUCTS MARKET, BY APPLICATION 237
9.1 INTRODUCTION 238
9.2 THERAPEUTICS 238
9.2.1 ANTIBODY-DRUG CONJUGATES 243
9.2.1.1 Increasing demand for targeted cancer therapies to propel market 243
9.2.2 PEPTIDE-DRUG CONJUGATES 246
9.2.2.1 Advancements in peptide synthesis to boost demand 246
9.2.3 PROTEIN-DRUG CONJUGATES 250
9.2.3.1 Improvements in bioavailability and pharmacokinetics of therapeutic agents to drive market 250
9.2.4 OTHER THERAPEUTIC APPLICATIONS 253
9.3 RESEARCH & DEVELOPMENT 256
9.3.1 GROWING INTEREST IN INNOVATIVE THERAPEUTIC MODALITIES TO DRIVE MARKET 256
9.4 DIAGNOSTICS 259
9.4.1 UTILIZATION IN DIAGNOSTIC ASSAY DEVELOPMENT TO SUPPORT MARKET GROWTH 259
 
10 BIOCONJUGATION PRODUCTS MARKET, BY END USER 263
10.1 INTRODUCTION 264
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 264
10.2.1 INCREASING ADOPTION OF BIOCONJUGATION IN TARGETED THERAPIES TO DRIVE MARKET 264
10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 268
10.3.1 INCREASING OUTSOURCING OF BIOCONJUGATION SERVICES TO PROPEL MARKET 268
10.4 ACADEMIC & RESEARCH INSTITUTES 271
10.4.1 INCREASING FOCUS ON NOVEL BIOCONJUGATION TECHNIQUES FOR BASIC & APPLIED RESEARCH TO FUEL UPTAKE 271
10.5 HOSPITALS AND CLINICAL/DIAGNOSTIC LABORATORIES 274
10.5.1 EXPANDING APPLICATIONS OF BIOCONJUGATES IN DIAGNOSTICS & THERAPEUTICS TO SUPPORT MARKET GROWTH 274
11 BIOCONJUGATION SERVICES MARKET, BY TYPE 278
11.1 INTRODUCTION 279
11.2 CUSTOM SYNTHESIS & CONJUGATION SERVICES 279
11.2.1 GROWING NEED FOR TARGETED & CUSTOMIZED THERAPIES TO DRIVE MARKET 279
11.3 ANALYTICAL & CHARACTERIZATION SERVICES 283
11.3.1 GROWING FOCUS ON REGULATORY COMPLIANCE TO FUEL UPTAKE 283
11.4 SCALE-UP & MANUFACTURING SERVICES 286
11.4.1 INCREASING COMMERCIALIZATION OF BIOCONJUGATED DRUGS TO SUPPORT MARKET GROWTH 286
11.5 OTHER SERVICES 289
12 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE 292
12.1 INTRODUCTION 293
12.2 ANTIBODY CONJUGATION 293
12.2.1 ABILITY TO LINK ANTIBODIES TO PAYLOADS FOR SPECIALIZED THERAPEUTICS TO PROPEL MARKET 293
12.3 PEPTIDE CONJUGATION 297
12.3.1 IMPROVED STABILITY & BIOAVAILABILITY TO DRIVE MARKET 297
12.4 PROTEIN CONJUGATION 300
12.4.1 LINKING PROTEINS WITH DRUGS FOR TARGETED DELIVERY TO FUEL UPTAKE 300
12.5 OLIGONUCLEOTIDE CONJUGATION 304
12.5.1 ADVANCEMENTS IN NUCLEIC ACID-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH 304
12.6 OTHER CONJUGATION SERVICES 307
 
13 BIOCONJUGATION SERVICES MARKET, BY TECHNIQUE 311
13.1 INTRODUCTION 312
13.2 CHEMICAL CONJUGATION 312
13.2.1 ESSENTIAL TECHNIQUE FOR DEVELOPMENT OF CUSTOM BIOCONJUGATES TO FUEL UPTAKE 312
13.3 CLICK CHEMISTRY 316
13.3.1 PROVISION OF HIGH YIELD FOR DEVELOPMENT OF COMPLEX BIOCONJUGATES TO PROPEL MARKET 316
13.4 ENZYME-MEDIATED CONJUGATION 319
13.4.1 NEED FOR PRECISE & STABLE CONJUGATES IN COMPLEX THERAPEUTIC MODALITIES TO DRIVE MARKET 319
13.5 PHOTOREACTIVE CROSSLINKING 322
13.5.1 ABILITY TO PROVIDE CONTROLLED & SITE-SPECIFIC FORMATION OF CROSSLINKS TO SUPPORT MARKET GROWTH 322
13.6 OTHER TECHNIQUES 325
14 BIOCONJUGATION SERVICES MARKET, BY APPLICATION 328
14.1 INTRODUCTION 329
14.2 THERAPEUTICS 329
14.2.1 STRATEGIC PARTNERSHIPS BETWEEN BIOPHARMA COMPANIES AND BIOCONJUGATION SERVICE PROVIDERS TO PROPEL MARKET 329
14.3 RESEARCH & DEVELOPMENT 333
14.3.1 GROWING FOCUS ON BIOMOLECULAR RESEARCH INNOVATION TO DRIVE MARKET 333
14.4 DIAGNOSTICS 336
14.4.1 DEVELOPMENT OF ADVANCED IMAGING TECHNOLOGIES AND BIOSENSORS TO SUPPORT MARKET GROWTH 336
15 BIOCONJUGATION SERVICES MARKET, BY END USER 340
15.1 INTRODUCTION 341
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 341
15.2.1 ADVANCEMENTS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 341
15.3 ACADEMIC & RESEARCH INSTITUTES 345
15.3.1 INNOVATION IN CONJUGATION TECHNIQUES AND BIOMEDICAL RESEARCH TO DRIVE MARKET 345
15.4 HOSPITALS AND CLINICAL/DIAGNOSTIC LABORATORIES 348
15.4.1 INCREASING DEMAND FOR PRECISION DIAGNOSTICS TO FUEL UPTAKE 348
16 BIOCONJUGATION MARKET, BY REGION 351
16.1 INTRODUCTION 352
16.2 NORTH AMERICA 353
16.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 362
16.2.2 US 362
16.2.2.1 High healthcare expenditure to propel market 362
16.2.3 CANADA 369
16.2.3.1 Increasing government funding for drug development to support market growth 369
16.3 EUROPE 376
16.3.1 EUROPE: MACROECONOMIC OUTLOOK 383
16.3.2 GERMANY 384
16.3.2.1 Facility expansion by key players to aid market growth 384
16.3.3 UK 391
16.3.3.1 Increased cancer prevalence and government funding for pharmaceutical & biotechnology research to fuel uptake 391
16.3.4 FRANCE 397
16.3.4.1 Favorable government initiatives and growing demand for personalized therapeutics to boost demand 397
16.3.5 ITALY 403
16.3.5.1 Increasing industrial collaborations for ADC production to support market growth 403
16.3.6 SPAIN 409
16.3.6.1 Growing preference for personalized medicine to drive market 409
16.3.7 REST OF EUROPE 415
16.4 ASIA PACIFIC 422
16.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 430
16.4.2 CHINA 431
16.4.2.1 Expansion of biopharmaceutical manufacturing facilities to boost demand 431
16.4.3 JAPAN 438
16.4.3.1 Increasing collaborations among biotechnology companies to support market growth 438
16.4.4 INDIA 445
16.4.4.1 High investments in pharma R&D and favorable government policies to boost demand 445
16.4.5 SOUTH KOREA 451
16.4.5.1 Increased focus on quality manufacturing practices to propel market 451
16.4.6 AUSTRALIA 458
16.4.6.1 Growing demand for innovative research solutions to drive market 458
16.4.7 REST OF ASIA PACIFIC 464
16.5 LATIN AMERICA 471
16.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 478
16.5.2 BRAZIL 479
16.5.2.1 Increasing pharmaceutical R&D to fuel market 479
16.5.3 MEXICO 486
16.5.3.1 High FDIs and reduced pharmaceutical manufacturing costs to drive market 486
16.5.4 REST OF LATIN AMERICA 492
 
16.6 MIDDLE EAST 499
16.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 506
16.6.2 GCC COUNTRIES 507
16.6.2.1 Kingdom of Saudi Arabia 514
16.6.2.1.1 Rising healthcare expenditure to boost market 514
16.6.2.2 United Arab Emirates 521
16.6.2.2.1 Increasing collaborations among biopharma companies to aid market growth 521
16.6.2.3 Other GCC Countries 527
16.6.3 REST OF MIDDLE EAST 534
16.7 AFRICA 541
16.7.1 INCREASING TARGET PATIENT POOL TO SUPPORT MARKET GROWTH 541
16.7.2 AFRICA: MACROECONOMIC OUTLOOK 547
17 COMPETITIVE LANDSCAPE 549
17.1 OVERVIEW 549
17.2 KEY PLAYER STRATEGY/RIGHT TO WIN 549
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOCONJUGATION MARKET 550
17.3 REVENUE ANALYSIS 551
17.4 MARKET SHARE ANALYSIS 552
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 554
17.5.1 STARS 554
17.5.2 EMERGING LEADERS 554
17.5.3 PERVASIVE PLAYERS 554
17.5.4 PARTICIPANTS 555
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 556
17.5.5.1 Company footprint 556
17.5.5.2 Product/Service footprint 557
17.5.5.3 Application footprint 558
17.5.5.4 End-user footprint 559
17.5.5.5 Region footprint 560
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 562
17.6.1 PROGRESSIVE COMPANIES 562
17.6.2 RESPONSIVE COMPANIES 562
17.6.3 DYNAMIC COMPANIES 562
17.6.4 STARTING BLOCKS 562
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 564
17.7 COMPANY VALUATION & FINANCIAL METRICS 566
17.7.1 FINANCIAL METRICS 566
17.7.2 COMPANY VALUATION 567
17.8 BRAND/PRODUCT/SERVICE COMPARISON 568
 
17.9 COMPETITIVE SCENARIO 569
17.9.1 PRODUCT/SERVICE LAUNCHES 569
17.9.2 DEALS 570
17.9.3 EXPANSIONS 571
18 COMPANY PROFILES 573
18.1 KEY PLAYERS 573
18.1.1 DANAHER CORPORATION 573
18.1.1.1 Business overview 573
18.1.1.2 Products/Services offered 574
18.1.1.3 Recent developments 582
18.1.1.3.1 Product/Service launches 582
18.1.1.3.2 Deals 583
18.1.1.3.3 Expansions 583
18.1.1.4 MnM view 584
18.1.1.4.1 Key strengths 584
18.1.1.4.2 Strategic choices 584
18.1.1.4.3 Weaknesses & competitive threats 585
18.1.2 LONZA 586
18.1.2.1 Business overview 586
18.1.2.2 Products/Services offered 587
18.1.2.3 Recent developments 588
18.1.2.3.1 Deals 588
18.1.2.3.2 Expansions 588
18.1.2.4 MnM view 589
18.1.2.4.1 Key strengths 589
18.1.2.4.2 Strategic choices 589
18.1.2.4.3 Weaknesses & competitive threats 589
18.1.3 THERMO FISHER SCIENTIFIC INC. 590
18.1.3.1 Business overview 590
18.1.3.2 Products/Services offered 591
18.1.3.3 Recent developments 597
18.1.3.3.1 Product/Service launches 597
18.1.3.3.2 Deals 598
18.1.3.3.3 Expansions 598
18.1.3.4 MnM view 599
18.1.3.4.1 Key strengths 599
18.1.3.4.2 Strategic choices 599
18.1.3.4.3 Weaknesses & competitive threats 600
 
18.1.4 MERCK KGAA 601
18.1.4.1 Business overview 601
18.1.4.2 Products/Services offered 602
18.1.4.3 Recent developments 606
18.1.4.3.1 Product/Service launches 606
18.1.4.3.2 Deals 607
18.1.4.3.3 Expansions 607
18.1.4.4 MnM view 609
18.1.4.4.1 Key strengths 609
18.1.4.4.2 Strategic choices 609
18.1.4.4.3 Weaknesses & competitive threats 609
18.1.5 ABBVIE INC. 610
18.1.5.1 Business overview 610
18.1.5.2 Products/Services offered 611
18.1.5.3 Recent developments 611
18.1.5.3.1 Deals 611
18.1.5.3.2 Expansions 612
18.1.5.4 MnM view 612
18.1.5.4.1 Key strengths 612
18.1.5.4.2 Strategic choices 612
18.1.5.4.3 Weaknesses & competitive threats 612
18.1.6 WUXI BIOLOGICS (CAYMAN) INC. 613
18.1.6.1 Business overview 613
18.1.6.2 Products/Services offered 614
18.1.6.3 Recent developments 615
18.1.6.3.1 Deals 615
18.1.6.3.2 Expansions 616
18.1.7 SARTORIUS AG 617
18.1.7.1 Business overview 617
18.1.7.2 Products/Services offered 618
18.1.7.3 Recent developments 620
18.1.7.3.1 Deals 620
18.1.7.3.2 Expansions 621
18.1.8 BIO-RAD LABORATORIES, INC. 623
18.1.8.1 Business overview 623
18.1.8.2 Products/Services offered 624
18.1.9 CATALENT, INC. 628
18.1.9.1 Business overview 628
18.1.9.2 Products/Services offered 629
18.1.9.3 Recent developments 630
18.1.9.3.1 Product/Service launches 630
18.1.9.3.2 Deals 630
18.1.9.3.3 Expansions 631
18.1.10 BECKTON, DICKINSON AND COMPANY 632
18.1.10.1 Business overview 632
18.1.10.2 Products/Services offered 633
18.1.10.3 Recent developments 635
18.1.10.3.1 Product/Service launches 635
18.1.10.3.2 Deals 635
18.1.11 AGILENT TECHNOLOGIES, INC. 636
18.1.11.1 Business overview 636
18.1.11.2 Products/Services offered 637
18.1.11.3 Recent developments 638
18.1.11.3.1 Product/Service launches 638
18.1.11.3.2 Deals 639
18.1.11.3.3 Expansions 640
18.1.12 PROMEGA CORPORATION 641
18.1.12.1 Business overview 641
18.1.12.2 Products/Services offered 641
18.1.13 F. HOFFMANN-LA ROCHE LTD. 642
18.1.13.1 Business overview 642
18.1.13.2 Products/Services offered 643
18.1.14 CHARLES RIVER LABORATORIES 645
18.1.14.1 Business overview 645
18.1.14.2 Products/Services offered 646
18.1.14.3 Recent developments 647
18.1.14.3.1 Deals 647
18.1.15 GENSCRIPT BIOTECH CORPORATION 648
18.1.15.1 Business overview 648
18.1.15.2 Products/Services offered 649
18.1.15.3 Recent developments 650
18.1.15.3.1 Deals 650
18.1.16 PIRAMAL PHARMA LIMITED 651
18.1.16.1 Business overview 651
18.1.16.2 Products/services offered 652
18.1.16.3 Recent developments 653
18.1.16.3.1 Product/Service launches 653
18.1.16.3.2 Expansions 653
18.2 OTHER PLAYERS 654
18.2.1 ABZENA LTD. 654
18.2.2 NEW ENGLAND BIOLABS 655
18.2.3 BIOSYNTH 656
18.2.4 CELL SIGNALING TECHNOLOGY, INC. 657
18.2.5 CREATIVE BIOLABS 658
18.2.6 FORMOSA LABORATORIES INC. 659
18.2.7 NJ BIO, INC. 660
18.2.8 ROCKLAND IMMUNOCHEMICALS, INC. 661
18.2.9 SHANGHAI CHEMPARTNER 662
18.2.10 STERLING PHARMA SOLUTIONS LIMITED 662
18.2.11 SYNGENE INTERNATIONAL LIMITED 663
18.2.12 TOKYO CHEMICAL INDUSTRY CO., LTD. 664
18.2.13 VECTOR LABORATORIES, INC. 665
19 APPENDIX 666
19.1 DISCUSSION GUIDE 666
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 672
19.3 CUSTOMIZATION OPTIONS 674
19.4 RELATED REPORTS 675
19.5 AUTHOR DETAILS 676